These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38194219)

  • 41. A Survey on the Management of Thyroid Eye Disease Among American and European Thyroid Association Members.
    Brito JP; Nagy EV; Singh Ospina N; Zˇarković M; Dosiou C; Fichter N; Lucarelli MJ; Hegedüs L
    Thyroid; 2022 Dec; 32(12):1535-1546. PubMed ID: 35946071
    [No Abstract]   [Full Text] [Related]  

  • 42. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease.
    Stein JD; Childers D; Gupta S; Talwar N; Nan B; Lee BJ; Smith TJ; Douglas R
    JAMA Ophthalmol; 2015 Mar; 133(3):290-6. PubMed ID: 25502604
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.
    Lanzolla G; Vannucchi G; Ionni I; Campi I; Sileo F; Lazzaroni E; Marinò M
    Front Endocrinol (Lausanne); 2019; 10():933. PubMed ID: 32038490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thyroid eye disease: therapy in the active phase.
    Bhatti MT; Dutton JJ
    J Neuroophthalmol; 2014 Jun; 34(2):186-97. PubMed ID: 24821102
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
    Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
    Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
    Krassas GE
    Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Monoclonal antibodies in the treatment of thyroid eye disease].
    Cheredanova VR; Poteshkin YE
    Vestn Oftalmol; 2021; 137(4):116-122. PubMed ID: 34410066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thyroid eye disease: current and potential medical management.
    Pouso-Diz JM; Abalo-Lojo JM; Gonzalez F
    Int Ophthalmol; 2020 Apr; 40(4):1035-1048. PubMed ID: 31919775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statins for Smith-Lemli-Opitz syndrome.
    Ballout RA; Livinski A; Fu YP; Steiner RD; Remaley AT
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013521. PubMed ID: 36373961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
    Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Editorial: News in Graves' orbitopathy: patients management and treatments.
    Lanzolla G; Sabini E
    Front Endocrinol (Lausanne); 2023; 14():1270467. PubMed ID: 37664861
    [No Abstract]   [Full Text] [Related]  

  • 54. HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
    Lewicki M; Ng I; Schneider AG
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010480. PubMed ID: 25758322
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.
    Sanders RD; Nicholson A; Lewis SR; Smith AF; Alderson P
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD009971. PubMed ID: 23824754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
    Wall JR; Lahooti H
    Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel.
    Zloto O; Sagiv O; Priel A; Cukierman-Yaffe T; Tirosh A; Agmon-Levin N; Madgar S; Serlin T; Ben Simon G
    Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):2009-2015. PubMed ID: 33528651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors.
    Bartalena L; Gallo D; Tanda ML; Kahaly GJ
    Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S2-S8. PubMed ID: 38054980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
    Wall JR; Lahooti H
    Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thyroid eye disease in Eastern Province of Saudi Arabia: clinical profile and correlation with vitamin D deficiency.
    Alali M; Alkulaib NS; Alkhars A; Albadri K; Al Hassan S; Elewa M; Aldairi W; Alsaqer SK; Al-Abdulqader RA; Alhammad F
    Orbit; 2024 Feb; 43(1):28-32. PubMed ID: 36855900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.